Securing Psilocybin API for Clinical Trials: Navigating the Global Supply Chain

Sourcing psilocybin API for a clinical trial is unlike procuring virtually any other pharmaceutical ingredient. The compound is a controlled substance in nearly every jurisdiction. The number of qualified, GMP-certified suppliers globally can be counted on one hand. And the regulatory pathway from manufacturer to clinical site crosses multiple national controlled substance frameworks, each with its own permitting requirements, timelines, and documentation standards.

For clinical trial sponsors and Contract Research Organizations (CROs) navigating this landscape for the first time, the procurement process alone can add months to a trial timeline if not planned proactively. This article maps the key steps and considerations.

The Supply Landscape Today

The current global supply of pharmaceutical-grade psilocybin API is concentrated among a very small number of producers. The largest synthetic producer is the Compass Pathways/Lonza partnership, which manufactures COMP360 primarily for Compass's own clinical programs. Among natural-extraction producers, Optimi Health in Canada holds the largest production capacity, with a Health Canada quota for significant volumes. Other suppliers include Purisys (synthetic, USA), PsyLabs (natural, South Africa), and Filament Health (natural, Canada).

For sponsors whose programs are not affiliated with one of these existing suppliers, securing a reliable, independent API source is a genuine strategic challenge — and one that becomes more pressing as the number of active psilocybin clinical trials continues to grow.

Step 1: Regulatory Groundwork

Before a single gram of psilocybin can be ordered, the sponsor must secure the necessary regulatory authorizations in their own jurisdiction. The specific requirements vary by country but typically include a controlled substance research license or clinical trial authorization from the national drug regulatory authority, a Schedule/narcotics researcher license from the national narcotics control body, ethics committee or Institutional Review Board (IRB) approval for the clinical protocol, and an import permit specific to the substance, quantity, and supplier.

In the United States, this means a DEA Schedule I Researcher Registration (or, if using an IND, the registration associated with the clinical program). In Australia, it requires both TGA clinical trial notification/approval and ODC import permits. In Canada, a Health Canada exemption under Section 56 of the CDSA or authorization through the Special Access Programme is required.

Step 2: Supplier Qualification

Once the regulatory framework is in place, the sponsor must identify and qualify a suitable API supplier. For psilocybin, supplier qualification should cover several critical dimensions.

Regulatory status: Does the supplier hold a valid narcotics/controlled substance manufacturing license in their jurisdiction? Is the facility GMP-certified, and by which authority? Can the supplier provide a Drug Master File (DMF) or equivalent regulatory dossier to support the sponsor's own regulatory filings?

Quality systems: What is the validated purity specification? What analytical methods are used, and are they pharmacopeial or validated in-house? What stability data is available? What is the batch-to-batch consistency based on historical production records?

Supply reliability: What is the production capacity versus current commitments? What is the standard lead time from order to delivery? Does the supplier have experience navigating international controlled substance export permits?

Export capability: Can the supplier obtain export permits to the sponsor's jurisdiction? Does the supplier have established logistics partnerships for controlled substance international shipping? What documentation does the supplier provide with each shipment (Certificate of Analysis, export permit copies, chain of custody records)?

Step 3: The Import/Export Permit Dance

International trade in psilocybin requires coordinated permits from both the exporting and importing countries. This is often the most time-consuming and error-prone step in the supply chain.

The typical sequence is as follows. The importer (sponsor/CRO) applies for an import permit from their national authority, specifying the substance, quantity, and exporting entity. Once the import permit is issued, a copy is provided to the manufacturer. The manufacturer uses the import permit to apply for an export permit from their national authority (in Thailand, this is the ONCB). Once both permits are in hand, the shipment can proceed — but both permits typically have validity windows, so the logistics must be coordinated to ensure the shipment occurs within the permitted timeframe.

For multi-site international trials requiring shipments to multiple countries, each destination requires its own import/export permit pair. This multiplies the administrative burden and makes centralized coordination essential.

Step 4: Logistics and Cold Chain

Psilocybin API, once purified and properly dried, is relatively stable under standard pharmaceutical storage conditions. However, controlled substance logistics add complexity beyond normal pharmaceutical shipping.

Shipments must be handled by logistics providers licensed to transport controlled substances internationally. The packaging and labeling must comply with both the exporting and importing country's requirements for controlled substance transport. Chain of custody documentation must be maintained from the manufacturer's secure storage through to the sponsor's receiving facility. And the receiving facility must have appropriate controlled substance storage infrastructure (typically a DEA-registered vault or equivalent) and qualified personnel to receive and inventory the material.

Step 5: Ongoing Supply Management

For clinical programs spanning multiple years and multiple dosing cohorts, psilocybin supply management is an ongoing process, not a one-time procurement. Sponsors should plan for regular re-ordering with sufficient lead time to accommodate permit processing, stability monitoring and potential re-testing of stored API before use, supplier relationship management to ensure continued priority allocation, and contingency planning in case of supply disruption — an especially important consideration given the small number of qualified global suppliers.

The Case for Supply Diversification

The concentration of global psilocybin API supply among a very small number of producers creates a meaningful supply chain risk for the entire clinical development ecosystem. A production disruption at a single facility, a regulatory change in a single jurisdiction, or even a commercial decision by a dominant supplier to prioritize internal programs over external customers could leave clinical trials without material.

This is one reason the emergence of new qualified suppliers — in Thailand and elsewhere — is strategically important for the field. Supply diversification reduces single-point-of-failure risk and creates the competitive dynamics that drive quality improvement and cost optimization over time.

The psilocybin supply chain is not just a procurement problem — it's a strategic risk management challenge. The sponsors who plan ahead, qualify multiple suppliers, and build relationships early will have a material advantage as the field scales.